New shot could help lower stubborn high cholesterol
NCT ID NCT07253584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested an injectable drug called SAL003 in 720 adults with high cholesterol or mixed dyslipidemia. Participants were already on statins but still had high LDL cholesterol. The study compared SAL003 to a placebo to see if it safely lowers cholesterol further. The main goal was the percent change in LDL cholesterol after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAL003 (an anti-PCSK9 monoclonal antibody injection)
- What this could lead to
- If successful, SAL003 could offer a new option to lower stubborn high cholesterol when statins alone aren't enough, potentially reducing heart disease risk.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet public. The drug may not show enough benefit over placebo, or side effects could limit its use. It's also an add-on to statins, not a standalone treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIAS, HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi’an, Shanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.